MPTP: Insights into parkinsonian neurodegeneration
Identifieur interne : 003502 ( Main/Curation ); précédent : 003501; suivant : 003503MPTP: Insights into parkinsonian neurodegeneration
Auteurs : Samuel G. Speciale [États-Unis]Source :
- Neurotoxicology and teratology [ 0892-0362 ] ; 2002.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Singe.
English descriptors
- KwdEn :
Abstract
MPTP burst upon the medical landscape two decades ago, first as a mysterious parkinsonian epidemic, triggering an unparalleled quest for the toxin's identity, and closely followed by an intense pursuit of its cellular mechanisms of action MPTP treatment created an animal model of many features of Parkinson's disease (PD), used primarily in primates and later in mice. The critical role of oxidative stress damage to vulnerable dopamine neurons, as well as for neurodegenerative diseases in general, emerged from MPTP neurotoxicity. A remarkable cross-ferrtilization of basic and clinical findings, including genetic and epidemiologic studies, has greatly advanced our understanding of PD and revealed multiple factors contributing to the parkinsonian phenotypes. Brain imaging localizes sites of action and provides potential presymptomatic diagnostic testing. Epidemiologic reports linking PD with pesticide exposure were complimented by supportive evidence from biochemical studies of MPTP and structurally related compounds, especially after low-level, long-term exposure. Genetic studies on the role of risk genes, such as α-synuclein or parkin, have been validated by biochemical, anatomical and neurochemical investigations showing factors interacting to produce pathophysiology in the animal model. Focusing on the pivotal role of mitochondria, subcellular pathways participating in cell death have been clarified by unraveling similar sites of action of MPTP. Along the way, compounds antagonizing or potentiating MPTP effects indicated new PD therapies, some of the former achieving clinical trials. The future is encouraging for combating PD and will continue to benefit from the MPTP neurotoxicity model.
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001030
- to stream PascalFrancis, to step Curation: Pour aller vers cette notice dans l'étape Curation :000404
- to stream PascalFrancis, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :000F24
- to stream Main, to step Merge: Pour aller vers cette notice dans l'étape Curation :003A39
Links to Exploration step
Pascal:03-0017901Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">MPTP: Insights into parkinsonian neurodegeneration</title><author><name sortKey="Speciale, Samuel G" sort="Speciale, Samuel G" uniqKey="Speciale S" first="Samuel G." last="Speciale">Samuel G. Speciale</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Department of Psychiatry, University of Texas Southwestern Medical School</s1><s2>Dallas, TX 75390</s2><s3>USA</s3><sZ>1 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Texas</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">03-0017901</idno><date when="2002">2002</date><idno type="stanalyst">PASCAL 03-0017901 INIST</idno><idno type="RBID">Pascal:03-0017901</idno><idno type="wicri:Area/PascalFrancis/Corpus">001030</idno><idno type="wicri:Area/PascalFrancis/Curation">000404</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">000F24</idno><idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000F24</idno><idno type="wicri:doubleKey">0892-0362:2002:Speciale S:mptp:insights:into</idno><idno type="wicri:Area/Main/Merge">003A39</idno><idno type="wicri:Area/Main/Curation">003502</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">MPTP: Insights into parkinsonian neurodegeneration</title><author><name sortKey="Speciale, Samuel G" sort="Speciale, Samuel G" uniqKey="Speciale S" first="Samuel G." last="Speciale">Samuel G. Speciale</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Department of Psychiatry, University of Texas Southwestern Medical School</s1><s2>Dallas, TX 75390</s2><s3>USA</s3><sZ>1 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Texas</region></placeName></affiliation></author></analytic><series><title level="j" type="main">Neurotoxicology and teratology</title><title level="j" type="abbreviated">Neurotoxicol. teratol.</title><idno type="ISSN">0892-0362</idno><imprint><date when="2002">2002</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Neurotoxicology and teratology</title><title level="j" type="abbreviated">Neurotoxicol. teratol.</title><idno type="ISSN">0892-0362</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animal model</term><term>Experimental disease</term><term>Mechanism of action</term><term>Monkey</term><term>Mouse</term><term>Parkinson disease</term><term>Review</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Pyridine(1-méthyl-4-phényl-1,2,3,6-tétrahydro)</term><term>Pathologie expérimentale</term><term>Modèle animal</term><term>Parkinson maladie</term><term>Singe</term><term>Souris</term><term>Mécanisme action</term><term>Article synthèse</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Singe</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">MPTP burst upon the medical landscape two decades ago, first as a mysterious parkinsonian epidemic, triggering an unparalleled quest for the toxin's identity, and closely followed by an intense pursuit of its cellular mechanisms of action MPTP treatment created an animal model of many features of Parkinson's disease (PD), used primarily in primates and later in mice. The critical role of oxidative stress damage to vulnerable dopamine neurons, as well as for neurodegenerative diseases in general, emerged from MPTP neurotoxicity. A remarkable cross-ferrtilization of basic and clinical findings, including genetic and epidemiologic studies, has greatly advanced our understanding of PD and revealed multiple factors contributing to the parkinsonian phenotypes. Brain imaging localizes sites of action and provides potential presymptomatic diagnostic testing. Epidemiologic reports linking PD with pesticide exposure were complimented by supportive evidence from biochemical studies of MPTP and structurally related compounds, especially after low-level, long-term exposure. Genetic studies on the role of risk genes, such as α-synuclein or parkin, have been validated by biochemical, anatomical and neurochemical investigations showing factors interacting to produce pathophysiology in the animal model. Focusing on the pivotal role of mitochondria, subcellular pathways participating in cell death have been clarified by unraveling similar sites of action of MPTP. Along the way, compounds antagonizing or potentiating MPTP effects indicated new PD therapies, some of the former achieving clinical trials. The future is encouraging for combating PD and will continue to benefit from the MPTP neurotoxicity model.</div></front></TEI></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/Main/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003502 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Curation/biblio.hfd -nk 003502 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= Main
|étape= Curation
|type= RBID
|clé= Pascal:03-0017901
|texte= MPTP: Insights into parkinsonian neurodegeneration
}}
| This area was generated with Dilib version V0.6.29. |  |